What are the NCCN guidelines on first-line treatment for metastatic or unresectable cutaneous melanoma?

Updated: Oct 13, 2020
  • Author: Susan M Swetter, MD; Chief Editor: Dirk M Elston, MD  more...
  • Print
Answer

Recommended first-line therapy (metastatic or unresectable disease):

  • Anti–programmed cell death protein 1 (PD1) monotherapy: Pembrolizumab, nivolumab

  • Combination targeted therapy for BRAF V600–activating mutation (preferred if clinically necessary for early response): Dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib

  • Useful in certain circumstances: Nivolumab/ipilimumab


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!